Skip to search formSkip to main contentSkip to account menu

pegaptanib

Known as: pegaptanib [Chemical/Ingredient] 
A 28-mer RNA aptamer covalently linked to two branched 20-kD polyethylene glycol (PEG) chains, with anti-angiogenic activity. Pegaptanib binds and… 
National Institutes of Health

Related topics

Related topics

6 relations
0.09 ML pegaptanib 3.33 MG/ML Prefilled Syringe [Macugen]Pegaptanib Sodium

Broader (1)

Aptamers, Nucleotide

Narrower (3)

EYE 001MacugenNX1838

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
ANTI-VEGF THERAPY FOR DIABETIC MACULAR EDEMA Anti-VEGF Therapy For Diabetic Macular Edema
2014
2014
Next-generation AMD drugs to wed blockbusters
Review
2013
Review
2013
Off-label drug use: the bevacizumab story.
2012
2012
Ranibizumab for eyes previously treated with pegaptanib or bevacizumab without clinical response.
BACKGROUND AND OBJECTIVE To assess the safety and efficacy of ranibizumab in patients who had inadequate response to pegaptanib… 
Review
2012
Review
2012
New Pharmacologic Approaches to Therapy for Age-Related Macular Degeneration
As a result of a better understanding of molecular mechanisms, a variety of new Pharmacologic treatments have recently been… 
Review
2011
Review
2011
Anti-angiogenesis drugs in diabetic retinopathy.
The vascular endothelial growth factor (VEGF) plays a key role in the development of proliferative diabetic retinopathy (PDR) and… 
2008
2008
Die Therapie der vaskularisierten serösen Pigmentepithelabhebung bei AMD – Beobachtungen nach Wechsel des intravitrealen Medikamentes bei Therapieversagen
Einleitung: Methode: Ergebnisse: Schlussfolgerungen: Introduction: Method: Results: Conclusion: 
2008
2008
Évolution des pratiques pour la réalisation des injections intravitréennes
2008
2008
Characterization of PEGylated Anti-VEGF aptamers using surface plasmon resonance
ConclusionsSPR analysis for the assessment of anti-VEGF RNA aptamer binding affinity was successfully carried out before and… 
Review
2008
Review
2008
Dégénérescence maculaire liée à l’âge exsudative : efficacité et limites des différents traitements
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)